Friday, July 10, 2026

Drug profile · INN

isavuconazole

isavuconazole (CRESEMBA) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antiinfectives for systemic use (J02) J02AC05
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — isavuconazole
Class
Antiinfectives for systemic use (J02)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

isavuconazole (CRESEMBA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN isavuconazole
Brand CRESEMBA
Therapeutic class Antiinfectives for systemic use (J02)
ATC code J02AC05

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. APHP180584 Phase 3 · PARItec · patients with acute respiratory failure from undetermined et
  2. FMGX-CS-302 Phase 3 · Anaxis Pharma · Invasive mold infections caused by Aspergillus spp., Fusariu
  3. Isavuconazole Phase 3 · Astellas Pharma · Candidiasis, Invasive

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is isavuconazole?

isavuconazole (CRESEMBA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for isavuconazole?

CRESEMBA is a marketed brand name for isavuconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.